Company
Every investor coverage indicates participated in a round Madorra raised.
Companies Madorra acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Madorra. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
OneVentures adds three women to senior investment and marketing roles as the Australian venture firm pushes growth in healthcare, biotech and women's health, alongside a Victorian Government-backed venture credit fund.
OneVentures has appointed three women to senior roles as it expands healthcare and biotech investing, with the Victorian Government backing a venture credit fund and the firm winning a diversity award.
The industry minister announced Biomedical Translation Fund backing: Brandon Capital invested $20 million in Respirion, OneVentures $4 million in Madorra, and $17.2 million went to an unnamed anti-fibrosis drug company.